Comparison of bronchoscopic and non-bronchoscopic techniques for diagnosis of ventilator associated pneumonia

G. C. Khilnani, T. K. Luqman Arafath, Vijay Hadda, Arti Kapil¹, Seema Sood¹, S. K. Sharma

Abstract

Background: The diagnosis of ventilator associated pneumonia (VAP) remains a challenge because the clinical signs and symptoms lack both sensitivity and specificity and the selection of microbiologic diagnostic procedure is still a matter of debate. Aims and Objective: To study the role of various bronchoscopic and non-bronchoscopic diagnostic techniques for diagnosis of VAP. Settings and Design: This prospective comparative study was conducted in a medical ICU of a tertiary care center. Materials and Methods: Twenty-five patients, clinically diagnosed with VAP, were evaluated by bronchoscopic and non-bronchoscopic procedures for diagnosis. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of various bronchoscopic and non-bronchoscopic techniques were calculated, taking clinical pulmonary infection score (CPIS) of ≥6 as reference standard. Results: Our study has shown that for the diagnosis of VAP, bronchoscopic brush had a sensitivity, specificity, PPV and NPV of 94.9% [confidence interval (CI): 70.6–99.7], 57.1% (CI: 13.4–86.1), 85% (CI: 61.1–96) and 80% (CI: 21.9–98.7), respectively. Bronchoscopic bronchoalveolar lavage (BAL) had a sensitivity, specificity, PPV and NPV of 77.8% (CI: 51.9–92.6), 71.8% (CI: 24.1–94), 87.3% (CI: 60.4–97.8) and 55.5% (CI: 17.4–82.6), respectively. Sensitivity, specificity, PPV and NPV for non-bronchoscopic BAL (NBAL) were 83.3% (CI: 57.7–95.6), 71.43% (CI: 24.1–94), 88.2% (CI: 62.3–97.4) and 62.5% (CI: 20.2–88.2), respectively. Endotracheal aspirate (ETA) yield was only 52% and showed poor concordance with BAL (κ=-0.351; P=0.064) and NBAL (κ=-0.272; P=0.161). There was a good microbiologic concordance among different bronchoscopic and non-bronchoscopic distal airway sampling techniques. Conclusion: NBAL is an inexpensive, easy, and useful technique for microbiologic diagnosis of VAP. Our findings, if verified, might simplify the approach for the diagnosis of VAP.

Keywords: Bronchoscopic brush, bronchoalveolar lavage, endotracheal aspirate, non-bronchoscopic bronchoalveolar lavage, ventilator associated pneumonia

Introduction

The diagnosis of ventilator associated pneumonia (VAP) remains a challenge because the clinical signs and symptoms lack both sensitivity and specificity and the selection of microbiologic diagnostic procedure is still a matter of debate.¹ Clinically, VAP is defined by four criteria: (1) the radiographic appearance of a new or progressive pulmonary infiltrates, (2) fever, (3) leukocytosis, and (4) purulent tracheobronchial secretions.² However, each of these signs or symptoms taken separately has limited diagnostic value and may also be seen in a noninfectious process.³,⁴ Pugin and
by numerous investigators as a clinical pulmonary infection score (CPIS) as a diagnostic tool for VAP and found that a CPIS of >6 was associated with a high likelihood of pneumonia with a sensitivity and a specificity of 93 and 100%, respectively.\[9\] Subsequently, Singh and colleagues validated this finding by using CPIS score successfully in reducing unnecessary antibiotic use in patients in whom VAP was suspected.\[6\]

Accurate clinical and microbiologic diagnosis of VAP is essential not only for selection of appropriate antimicrobials but also to prevent their misuse. Inappropriate use of antimicrobials in these patients leads to increased mortality and emergence of multidrug resistant pathogens in the ICU.\[7\] It has been postulated by numerous investigators that "invasive" diagnostic methods, including quantitative cultures of distal airway specimens obtained by using bronchoscopic bronchoalveolar lavage (BAL), bronchoscopic brush, protected BAL, or protected specimen brush (PSB), could improve identification of patients with true VAP and selection of appropriate antibiotics.\[8-10\] However, bronchoscopy requires technical expertise and adds to the cost of care. The results of the studies using bronchoscopic techniques are inconsistent, showing both false-positive and false-negative results, which further questions their exact role in the diagnosis of VAP.\[11,12\] In an attempt to overcome these limitations, non-bronchoscopic distal airway sampling methods have emerged, like non-bronchoscopic BAL (NBAL) and non-bronchoscopic PSB. Though simple and inexpensive, diagnostic accuracy of these blind sampling methods has not been studied in the Indian setting.

This study was designed to compare the diagnostic value of various methods of collecting respiratory samples which included bronchoscopic BAL and brushings, non-bronchoscopic protected BAL, and endotracheal aspirate (ETA) in patients with VAP.

**Materials and Methods**

This prospective comparative study was conducted in the medical intensive care unit (ICU) of a tertiary care center situated in northern India. The study was approved by the institutional review board. After obtaining written informed consent from either the patient or the first-degree relative, we enrolled 25 patients of age 18 years or more who required ventilatory support for the preceding 48 hours or more with clinical and radiological diagnosis of VAP.\[13\] Patients with diagnosis of community acquired pneumonia, immunocompromised state and bleeding diathesis were excluded. Similarly, patients who required mechanical ventilator in another hospital for 48 hours or more before admission to our institute and those who were extubated/weaned or died within 3 days of intubation were also excluded from the study. For each patient studied, these parameters were recorded: age, gender, primary diagnosis on admission, indication of mechanical ventilation, comorbid conditions (chronic obstructive airway disease, alcoholism, cardiac or neurological disease), Glasgow coma score, organ failure and severity scores assessed by APACHE II, duration of mechanical ventilation, and antibiotics received before samplings.

In each patient, four respiratory samples were collected which included ETA, bronchoscopic brush and BAL, and NBAL. To avoid contamination of the lower airways, the non-bronchoscopic sampling was performed first. The samples were obtained in sequential order of ETA followed by NBAL, then bronchoscopic brush and BAL. All the bronchoscopic samplings were done by the principal investigator (GCK) and non-bronchoscopic procedures by a junior resident doctor.

**Endotracheal aspirate and non-bronchoscopic BAL**

The ETA specimens were collected via a sputum suction trap. Non-bronchoscopic protected BAL was performed by double catheter technique. A sterile suction catheter of size 16 Fr was cut 2–3 cm from the distal end to give a final length of about 47–48 cm and inserted through the endotracheal tube and blindly advanced into the distal airways till resistance is felt. The catheter was wedged in that position, and a second, 50-cm long, sterile suction catheter of size 8 Fr was passed through the first catheter and advanced as far as possible. Twenty milliliters of normal saline was instilled into the distal airways through the inner tube and aspirate was collected in a sterile container [Figure 1]. Quantity of the aspirate was recorded. Procedure was repeated if the aspirated fluid was less than 5 ml. The samples were immediately transported for bacteriologic examination and quantitative cultures.

**Bronchoscopic BAL and brush**

Patients were sedated with 5 mg of intravenous midazolam. The ventilatory settings were adjusted by increasing tidal volume by 100 ml and \( \text{FiO}_2 \) to 1.0. All the vitals including heart rate, blood pressure and oxygen saturation were monitored using continuous pulse oximetry during the entire procedure.

The bronchoscope was introduced through the T-piece...
and the tip was positioned close to the orifice of the bronchus, draining the bronchopulmonary segment of interest as determined by chest radiograph. In patients with diffuse/bilateral lung infiltrates, bronchoscope was advanced into a bronchopulmonary segment of the right lower lobe for sampling. On reaching the area to be sampled, the brush was protruded, plunged a number of times into the suspected bronchus, and withdrawn. The sample was then transferred by stirring the brush into a sterile vial containing 1 ml of normal saline which was used for microbiologic analysis.

Bronchoscopic BAL was performed in the same lobe and segment/subsegment from which bronchoscopic brushings were obtained. After introducing the bronchoscope and wedging the tip in the selected segmental or sub-segmental bronchus, at least three aliquots of 25 ml buffered normal saline were instilled and gently aspirated by suction.

All the samples were transported to our microbiology laboratory within 1 hour of collection and further processing was done there as described below.

BAL fluid - Samples were divided into two, the first half was centrifuged (1500 rpm/minute for 10 minutes) and used for gram stain. The second half of the BAL sample was serially diluted with normal saline (1:10-1:10⁶) and used for quantification of bacterial load.

Bronchial brushing specimens - The samples were vortexed vigorously for 60 seconds to thoroughly suspend all the materials from the brush into the saline solution. This was examined microscopically following gram stain. Rest were serially diluted similar to BAL and used for culture.

ETA - ETA samples were used directly for staining and microbiologic culture by semi-quantitative method.

Ten µl of each dilution was transferred on to dry blood agar and Mc Conkey agar plate and spread properly. The plates were incubated at 35-37°C for 24 hours. Bacterial identification was done using standard microbiologic techniques and antibiotic sensitivity was estimated as per National Committee for Clinical Laboratory Standard (NCCLS). The growths were expressed as number of colony forming units (CFU)/ml. The thresholds applied to quantitative cultures for the diagnosis of VAP were 10³ CFU/ml for bronchoscopic brush sample and 10⁴ CFU/ml for non-bronchoscopic protected BAL and bronchoscopic BAL. ETA samples were cultured semi-quantitatively and were considered positive only when the same organism was isolated from other distal sampling techniques with their respective cut-off values.

The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of non-bronchoscopic protected BAL, bronchoscopic BAL and bronchoscopic brushings, for the diagnosis of VAP, were calculated taking CPIS score of 6 as reference standard. A kappa (κ) coefficient of agreement among these three diagnostic modalities was computed. Results were presented as mean ± SD and a P value of <0.05 was considered significant.

Results

We prospectively evaluated 25 patients with high clinical suspicion of VAP, between August 2002 to March 2004. General characteristics of the patients are shown in Table 1. There was a male preponderance in the study group with a male:female ratio of 17:8. Chronic obstructive pulmonary disease with type-II respiratory failure (14) was the commonest indication of mechanical ventilation. Other diseases include metabolic encephalopathy (2), cerebral vascular disease (2), acute inflammatory demyelinating polyneuropathy (1), acute disseminated encephalomyelitis (1), chronic liver disease (1), myotonic muscular dystrophy (1), organophosphorus poisoning (1), chronic renal failure with anemia (1), and sub-dural hematoma due to road traffic accident (1). Majority of patients, except two cases, were diagnosed to have late onset VAP. All patients in the study were on presumptive antibiotic treatment.

There was no significant complication observed during
or immediately after the sampling procedures. Overall mortality was 60%. No patient deaths were attributed to sampling techniques, either bronchoscopic or non-bronchoscopic.

Four samples (non-bronchoscopic protected BAL, bronchoscopic BAL, bronchoscopic brush and ETA) from each patient with high clinical suspicion of VAP were analyzed. The diagnostic utility of various sampling techniques is shown in Table 2. The yields of different sampling techniques were 80% for bronchoscopic brush, and 64 and 68% for bronchoscopic BAL and non-bronchoscopic protected BAL, respectively. For ETA, the samples’ yield was only 52%.

A definite clinical diagnosis of VAP, i.e., a CPIS score of ≥6, was present in 18 patients. Non-bronchoscopic protected BAL had a kappa measure of agreement of 0.525 (P = 0.017) with the clinical diagnosis of VAP. Sensitivity, specificity, PPV and NPV were 83.3% (CI: 57.7–95.6), 71.43% (CI: 24.1–94), 88.2% (CI: 62.3–97.4) and 62.5% (CI: 20.2–88.2), respectively. Percentage of concordance between non-bronchoscopic protected BAL and CPIS was 80%.

In our study, bronchoscopic brush samples showed the highest agreement with CPIS, with a kappa value of 0.565 (P = 0.012). It has shown a sensitivity of 94.9% (CI: 70.6–99.7) with specificity of 57.1% (CI: 13.4–86.1). PPV and NPV were 85% (CI: 61.1–96) and 80% (CI: 21.9–98.7), respectively. Bronchoscopic BAL had a sensitivity of 77.8% (CI: 51.9–92.6) and specificity of 71.8% (CI: 24.1–94). PPV and NPV were 87.3% (CI: 60.4–97.8) and 55.5% (CI: 17.4–82.6), respectively. The kappa measure of agreement with CPIS was 0.453 (P = 0.021) and percentage of concordance was 76%.

Among the different sampling techniques, we observed highest concordance for the type of microorganisms between non-bronchoscopic protected BAL and bronchoscopic brush. This was followed by non-bronchoscopic protected BAL and bronchoscopic BAL and two bronchoscopic techniques, BAL and brush [Table 3]. Semi-quantitative ETA culture showed low concordance rate with bronchoscopic (BAL and brush) as well as non-bronchoscopic techniques (BAL). However, it showed highest and statistically significant microbiologic concordance with bronchoscopic brush.

Microbial cultures were positive in 21 of 25 (84.0%) samples each of bronchoscopic brush and BAL. Non-bronchoscopic protected BAL and ETA samples grew pathologic microorganisms on 22 (88%) and 17 (68%) samples cultured, respectively. *Pseudomonas aeruginosa* was the most common organism isolated (44 of 100 samples), followed by *Acinetobacter* (37%), *Escherichia coli* and *Klebsiella* [Table 4]. Among these pathogens, 90% were extended spectrum beta-lactamase (ESBL) positive. Average number of organisms present per sample in ETA and non-bronchoscopic protected BAL were 0.88 and 1.28, respectively. For BAL and bronchoscopic brush, the numbers of organism in each sample were similar, i.e., 1.33 each. Perfect qualitative concordance (organism and antibiotic sensitivity) among all four techniques was seen in 9 out of 25 cases. When distal airway sampling techniques (non-bronchoscopic protected BAL, BAL and bronchoscopic brush) alone were considered, this increased to 21 out of 25.

**Discussion**

VAP is a common complication associated with invasive ventilator support and contributes to a significant

### Table 1: Baseline characteristics of patients

| Variables                        | Results [Mean ± SD (range)] |
|----------------------------------|----------------------------|
| Age (years)                      | 55.60 ± 16.17 (24–80)      |
| Duration of ICU stay (days)      | 29.52 ± 24 (9–106)         |
| Duration of mechanical ventilation (days) | 34.88 ± 32 (7–98) |
| Duration of development of VAP (days) | 18.44 ± 12.18 (4–57) |
| Duration of fever (days)         | 4.56 ± 3.14                |
| Duration of increased tracheal secretion (days) | 5.36 ± 2.18 |
| Leukocyte counts of the cohort (per mm³) | 12,447 ± 3592 |
| pO₂ of cohort (mm of Hg)         | 90 ± 19.18                 |
| pCO₂ of cohort (mm of Hg)        | 47.23 ± 25.12              |
| CPIS of cohort                   | 6.76 ± 1.67                |
| APACHE II                        | 23 ± 7.12                  |

CPIS – clinical pulmonary infection score

### Table 2: Diagnostic value of various sampling techniques

| Sampling techniques  | Yield | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|----------------------|-------|----------------------|----------------------|--------------|--------------|
| ETA                  | 52    | 55.6 (31.3–77.6)     | 71.4 (30.3–94.9)     | 83.3 (50.9–97.1) | 38.5 (15.1–67.7) |
| NPBAL                | 68    | 83.3 (57.7–95.6)     | 71.4 (24.1–94.0)     | 88.2 (62.3–97.4) | 62.5 (21.5–88.2) |
| BAL                  | 64    | 77.8 (51.9–92.6)     | 71.8 (24.1–94.0)     | 87.3 (60.4–97.8) | 55.5 (17.4–82.6) |
| B Brush              | 80    | 94.9 (70.6–99.7)     | 57.1 (13.4–86.1)     | 85 (61.1–96.0)  | 80 (21.9–98.7)  |

NPBAL – Non-bronchoscopic protected bronchoalveolar lavage; B brush – Bronchoscopic brush; ETA – Endotracheal aspirate; PPV – Positive predictive value; NPV – Negative predictive value
mortality and morbidity in these patients.\cite{14, 15} Because of poor specificity of the clinical diagnosis of VAP, reliance is often placed on radiologic and microbiologic diagnosis. Microbiologic diagnosis comprises culture of blood, pleural fluid and respiratory secretions including proximal (tracheal aspirate) and distal airways (BAL and brush). It is important to keep in mind that the sensitivity of blood culture for diagnosis of VAP is less than 25%, and even when positive, the organism may originate from an extrapulmonary site of infection in as many as 64% of cases, even when VAP is present.\cite{16}

ETA is the most commonly used method of airway sampling in ICUs all over the world. Gram stain, non-quantitative and semi-quantitative culture of tracheal secretions has the advantage of reproducibility and of requiring little technical expertise and no specialized equipment or technique. However, these studies add little to the sensitivity and specificity of the clinical diagnosis of VAP, as the upper respiratory tract is frequently colonized with potential pathogens, even in the absence of pneumonia.\cite{12, 17} Thus, if an organism is cultured or noted on gram stain, one does not know if it is the cause of pneumonia or simply colonization. Our study too questioned the value of microbiologic diagnosis of VAP based on ETA culture results by demonstrating its poor microbiologic agreement with distal airway sampling techniques. It highlights that ETA does not represent a true distal airway sample. Therefore, treating VAP based on ETA microbiology may not be the optimum management of these patients.

Studies from various countries have shown that bronchoscopic procedures are important part of evaluation of patients with VAP. However, these are associated with false-positive and false-negative results.\cite{18-20} Canadian Critical Care Trial group, in a large multicentric study, demonstrated that there was no difference in clinical outcome among patients treated for VAP based on bronchoscopic or non-bronchoscopic procedures.\cite{21} Further, in developing countries like India, this facility is not routinely available for patients admitted to ICU. Therefore, it is important to evaluate the role of non-bronchoscopic techniques in our setting. Our study has shown that NBAL has good sensitivity, specificity, PPV and NPV. Inherent advantages of non-bronchoscopic techniques include less invasiveness, lesser compromise of oxygenation, ventilation and respiratory mechanics during the procedure, less likelihood of increasing intracranial pressure and arrhythmia, lack of contamination through the bronchoscopic channel, and lower cost.

Although NBAL is a blind procedure, its concordance with bronchoscopic brush proves the fact that protected sample adequately represents the lower airway secretions (either side) and efficiently diagnoses VAP. The utility of NBAL for diagnosis of VAP has been demonstrated by other researchers also, both in clinical as well as autopsy

| Table 3: Concordance among various microbiologic sampling techniques |
|---|
| Sampling techniques | Kappa coefficient | % Concordance | P value |
| NPBAL vs. B brush | 0.694 | 88 | 0.001 |
| BAL vs. B brush | 0.423 | 76 | 0.04 |
| NPBAL vs. BAL | 0.56 | 80 | 0.01 |
| ETA vs. NPBAL | 0.351 | 68 | 0.064 |
| ETA vs. BAL | 0.272 | 64 | 0.161 |
| ETA vs. B brush | 0.426 | 72 | 0.009 |

NPBAL – Non-bronchoscopic protected bronchoalveolar lavage; B brush – Bronchoscopic brush; ETA – Endotracheal aspirate

| Table 4: Organisms isolated in microbiologic cultures |
|---|
| Various respiratory samples [n (%)] |
| Organisms | B. Brush | BAL | NPBAL | ETA |
| Sterile | 4 (16) | 4 (16) | 3 (12) | 8 (32) |
| Pseudomonas aeruginosa (ESBL +) | 6 (24) | 6 (24) | 6 (24) | 7 (28) |
| Pseudomonas aeruginosa (ESBL −) | 1 (4) | 1 (4) | 1 (4) | 1 (4) |
| Pseudomonas aeruginosa (ESBL −) and Acinetobacter spp. (ESBL +) | 1 (4) | 1 (4) | 1 (4) | Nil |
| Enterobacter spp. (ESBL +) and Pseudomonas aeruginosa (ESBL +) | 1 (4) | 1 (4) | 1 (4) | Nil |
| Klebsiella spp. (ESBL −) | 1 (4) | 1 (4) | 1 (4) | Nil |
| Acinetobacter spp. (ESBL +) and Escherichia coli (ESBL +) | 2 (8) | 2 (8) | 2 (8) | 3 (12) |
| Escherichia coli (ESBL +) | 5 (20) | 5 (20) | 5 (20) | 4 (16) |
| Pseudomonas aeruginosa (ESBL +) and Acinetobacter spp. (ESBL +) | 3 (12) | 3 (12) | 3 (12) | Nil |
| Acinetobacter spp. (ESBL −) | Nil | Nil | Nil | 1 (4) |
| Acinetobacter spp. (ESBL +) and Citrobacter (ESBL +) | Nil | Nil | Nil | 1 (4) |

B. brush – Bronchoscopic brush; BAL – Bronchoalveolar lavage; NPBAL – Non-bronchoscopic protected bronchoalveolar lavage; ETA – Endotracheal aspirate; ELBS – Extended spectrum beta-lactamase
We observed a good agreement for the type of microorganisms among bronchoscopic BAL, brush and non-bronchoscopic BAL. The predominant pathogens cultured were identical in 84% of samples. Kollef et al. in their study showed that NBAL done by a respiratory physiotherapist has shown good microbiologic agreement (83.3%) with bronchoscopic protected brush. These results signify that blind sampling techniques like NBAL are good modalities for microbiologic diagnosis of VAP. As shown in another recent trial, our study also highlights that ETA does not represent a true distal airway sample. The concordance of NBAL with bronchoscopic brush proves the fact that protected sample adequately represents lower airway secretions (either side) and accurately diagnoses VAP. Therefore, ETA should be replaced by NBAL for microbiologic diagnosis of VAP.

Theoretically, there may be concern of diluting the alveolar fluid for the bronchoscopic samples when invasive samples (BAL and brush) are obtained after the non-bronchoscopic samples (NBAL). However, most of the studies have followed this protocol and did not find significant effect of this dilution on microbiology of the sample. This effect will be further nullified by setting different thresholds for CFU/ml for each microbiologic sample, such as 10^4 for brush and 10^4 for BAL.

An important consideration in our study is the financial implications associated with providing these diagnostic procedures. Bronchoscopic procedures are expensive, require expertise and are not freely available, whereas NBAL is a simple procedure which can be performed by resident doctors and paramedics (nurses) posted at the ICU after a small demonstration. This will result in significant reduction in the cost of management of VAP as shown in a report by Kollef et al., where about $1000 was saved per substitution of bronchoscopic brush with NBAL. Similar benefits should be expected in our setting as the catheters and mucus extractor used in our study cost only ₹50 per patient. However, total savings depend both on these direct savings and on the balance of false-positive and false-negative results produced by these tests with their ensuing costs and patient charges.

An important limitation of our study is the validity of the exact operating characteristics (sensitivity, specificity, PPV, and NPV) for various sampling techniques, which may be questioned in the absence of the gold standard for the diagnosis of VAP. Autopsy examination of lung tissue (bacteriologic and histologic) has been used as a gold standard to determine the precise diagnostic yield of similar bronchoscopic and non-bronchoscopic procedures. However, this has a limitation that it is not useful in clinical decision making. The diagnostic utility of this approach may be further compromised due to histologic sampling errors, the effects of previous antibiotic administration on tissue cultures, and problems related to the timing of postmortem lung examination. It has been suggested that the diagnostic criteria used for VAP should have high sensitivity. This approach is based on the premise that the risk for not treating an individual patient with pneumonia probably outweighs the risk for unnecessary antibiotic administration. For this study, we used CPIS as the standard, which has high sensitivity for the diagnosis of VAP. However, there are other studies where usefulness of CPIS for the diagnosis of VAP was questioned. Therefore, one should keep this limitation in mind during interpretation of the results of our study.

Another important limitation of our study is a relatively small cohort. Larger studies from other parts of the world have shown comparable results. Indian data comparing these diagnostic modalities using independent criteria (histologic and blood or pleural fluid cultures) to establish the diagnosis of VAP are lacking; therefore, it is difficult to determine the exact operating characteristics (sensitivity, specificity, PPV and NPV) of these non-bronchoscopic techniques. Because of this lack of established diagnostic criterion standard, we could not perform a complete economic analysis; therefore, the effect of cost associated with the treatment of false-positive culture results cannot be commented upon.

Finally, one would expect that ETA will grow more organisms and will show false-positive results more frequently. However, our study has shown that ETA has a lower yield than NBAL, BAL and bronchoscopic
brush. Although empirical broad-spectrum antibiotics might have altered the microbiologic result, however, this would have a similar effect on other microbiologic samples. This has been observed previously in antibiotic-naïve as well as patients who were on empirical antibiotics.[22,34,36]

Till date, the optimal strategy for the diagnosis of VAP remains to be defined. The American Thoracic Society guidelines do provide expert opinion supporting quantitative or semi-quantitative cultures of respiratory specimens, although the panel favors invasive quantitative techniques. Our study has shown that NBAL is an acceptable alternative to bronchoscopy for the evaluation of suspected VAP. Therefore, our observations, if verified in other ICUs, might simplify the approach for the diagnosis of VAP. This conclusion is based on the fact that NBAL is relatively inexpensive, requires lesser expertise, and may be a useful method for the serial evaluation of suspected nosocomial pneumonia in patients on mechanical ventilation.

References

1. Hubmayr RD, Burehardhi H, Elliot M, Fessler H, Georgopoulos D, Juhran A, et al. Statement of the 4th International Consensus Conference in Critical Care on ICU-Acquired Pneumonia—Chicago, Illinois, May 2002. Intensive Care Med 2002;28:1521-36.
2. Johanson WG Jr, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract. Ann Intern Med 1972;77:701-6.
3. Andrews CP, Coalson JJ, Smith JD, Johanson WG Jr. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury. Chest 1981;80:254-8.
4. Fagon JY, Chastre J, Hance AJ, Donnart Y, Trouillet JL, Gibert C. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993;103:547-53.
5. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1211-9.
6. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505-11.
7. Zilberberg MD, Shorr AF, Miecz ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008;134:963-8.
8. Chastre J, Fagon JY, Bournet-Lecco M, Cahuat S, Donahy MC, al Khani R, et al. Evaluation of bronchoalveolar techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995;152:231-40.
9. Torres A, el-Ebiary M. Invasive diagnostic techniques for pneumonia: protected specimen brush, bronchoalveolar lavage, and lung biopsy methods. Infect Dis Clin North Am 1998;12:701-22.
10. Marquette CH, Copin MC, Wallet F, Neviere R, Sainhier F, Mathieu D, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995;151:1878-88.
11. Michaud S, Suzuki S, Harbarth S. Effect of design-related bias in studies of diagnostic tests for ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;166:1320-5.
12. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
13. Fartoukh M, Maize B, Honore S, Cof C, Zahar JR, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med 2003;168:173-9.
14. Wseke HJ, Bolling T, Schult I, Lode H. Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. Crit Care Med 2001;5:167-73.
15. Fagon JY, Chastre J, Hance AJ, Montrovers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
16. Luna CM, Videle A, Mattera J, Vay C, Faniglietti A, Vujevich P, et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999;116:1075-84.
17. Marquette CH, Georges H, Wallet F, Ramon P, Sainhier F, Neviere R, et al. Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. Am Rev Respir Dis 1993;148:138-44.
18. Estella A, Monge ML, Perez Fontaina L, Sainz de Baranda A, Gala MJ, Moreno E. Bronchoalveolar lavage for diagnosing pneumonia in mechanically ventilated patients. Med Intensiva 2008;32:419-23.
19. Heyland DK, Cook DJ, Marshall J, Heule M, Guslits B, Lang J, et al. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group. Chest 1999;115:1076-84.
20. Balthazar AB, Von Nowakowski A, De Capitaini EM, Bottini PV, Terzi RD, Arajo S. Diagnostic investigation of ventilator-associated pneumonia using bronchoalveolar lavage: comparative study with a postmortem lung biopsy. Braz J Med Biol Res 2001;34:993-1001.
21. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2819-30.
22. Rouly-JD, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jairier V, et al. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992;146:1059-66.
23. Papazian L, Thomas P, Garbe L, Guignon I, Thirion X, Charrel J, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med 1995;152:1892-91.
24. Kollef MH, Bock KR, Richards RD, Hearnan ML. The safety and diagnostic accuracy of minimbronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Am Intern Med 1995;122:743-8.
25. Rouly-JD, Rossignon MD, Nicolas MH, Martin de Lassale E, Cristin S, Grosset J, et al. A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia. Anesthesiology 1989;71:679-85.
26. Fujitani S, Cohen-Meuland MH, Mulltle RP, Delgado E, Tuira Y, Darby JM. Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia. Respir Care 2009;54:1453-61.
27. Fagon JY, Chastre J, Wolff M, Gervais C, Parcer-Aubas S, Stephan E, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000;132:621-30.
28. Chastre J, Vian F, Brun P, Pierre J, Dange MC, Bonehamma A, et al. Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am Rev Respir Dis 1984;130:924-9.
29. Torres A, el-Ebiary M, Patel L, Gonzalez J, de la Bellacasa JP, Ramirez C, et al. Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy. Am J Respir Crit Care Med 1994;149:324-31.
30. Basrkski VS, el-Torky M, Coalson JJ, Griffin JP. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia. Chest 1992;102:571-9.
pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures. Chest 1995;107:85-95.

32. Croce MA, Swanson JM, Magnotti LJ, Claridge JA, Weinberg JA, Wood GC, et al. The futility of the clinical pulmonary infection score in trauma patients. J Trauma 2006;60:523-7.

33. Schurink CA, Van Nieuwenhoven CA, Jacobs JA, Rozenberg-Arshak M, Joore HC, Buskens E, et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med 2004;30:217-24.

34. Brun-Buisson C, Fartoukh M, Lechapt E, Honore S, Zahar JR, Cerf C, et al. Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated pneumonia. Chest 2005;128:333-44.

35. Fagon JY, Chastre J, Hance AJ, Guiguet M, Trouillet JL, Donart Y, et al. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1988;138:110-6.

36. Medford AR, Husain SA, Turki HM, Millar AB. Diagnosis of ventilator-associated pneumonia. J Crit Care 2009;24:473.

Source of Support: Nil, Conflict of Interest: None declared.